Comparison of methods for calculating rectal dose after 125I prostate brachytherapy implants

被引:12
|
作者
Hilts, M
Spadinger, I
Keyes, M
机构
[1] BC Canc Agcy, Dept Phys Med, Vancouver Canc Ctr, Vancouver, BC V6R 2B6, Canada
[2] BC Canc Agcy, Dept Radiat Oncol, Vancouver Canc Ctr, Vancouver, BC V6R 2B6, Canada
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2002年 / 53卷 / 03期
关键词
rectal dose; prostate brachytherapy; post-implant dosimetry;
D O I
10.1016/S0360-3016(02)02798-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare several different methods of calculating the rectal dose and examine how accurately they represent rectal dose surface area measurements and, also, their practicality for routine use. Methods and Materials: This study comprised 55 patients, randomly selected from 295 prostate brachytherapy patients implanted at the Vancouver Cancer Center between 1998 and 2000. All implants used a nonuniform loading of 0.33 mCi (NIST-99) I-125 seeds and a prescribed dose of 144 Gy. Pelvic CT scans were obtained for each patient similar to30 days after implantation. For the purposes of calculating the rectal dose, several structures were contoured on the CT images: (1) a 1-mm-thick anterior rectal wall, (2) the anterior half rectum, and (3) the whole rectum. Point doses were also obtained along the anterior rectal surface. The thin wall contour provided a surrogate for a dose-surface histogram (DSH) and was our reference standard rectal dose measurement. Alternate rectal dose measurements (volume, surface area, and length of rectum receiving a dose of interest [DOI] of greater than or equal to144 Gy and 216 Gy, as well as point dose measures) were calculated using several methods (VariSeed software) and compared with the surrogate DSH measure (SA(DOI)). Results: The best correlation with SA(144Gy) was the dose volumes (whole or anterior half rectum) (R = 0.949). The length of rectum receiving greater than or equal to144 Gy also correlated well with SA(144Gy) (R greater than or equal to0.898). Point dose measures, such as the average and maximal anterior dose, correlated poorly with SA(144Gy) (R less than or equal to0.649). The 216-Gy measurements supported these results. In addition, dose-volume measurements were the most practical (similar to6 min/patient), with our surrogate DSH the least practical (similar to20 min/patient). Conclusion: Dose-volume measurements for the whole or anterior half rectum, because they were the most practical measures and best represented the DSH measurements, should be considered a standard method of reporting the rectal dose when calculating the DSH is not practical. Average or maximal anterior rectal doses are not reliable indicators of surface area dosimetry. (C) 2002 Elsevier Science Inc.
引用
收藏
页码:775 / 785
页数:11
相关论文
共 50 条
  • [41] A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy
    Reed, Daniel R.
    Wallner, Kent E.
    Merrick, Gregory S.
    ArthurS, Sandra
    Mueller, Amy
    Cavanagh, William
    Butler, Wayner B.
    Ford, Eric
    Sutlief, Steve G.
    BRACHYTHERAPY, 2007, 6 (02) : 129 - 134
  • [42] Single-nucleotide polymorphisms studied for associations with urinary toxicity from 125I prostate brachytherapy implants
    Usmani, Nawaid
    Leong, Nelson
    Martell, Kevin
    Lan, Lanna
    Ghosh, Sunita
    Pervez, Nadeem
    Pedersen, John
    Yee, Don
    Murtha, Albert
    Amanie, John
    Sloboda, Ron
    Murray, David
    Parliament, Matthew
    BRACHYTHERAPY, 2014, 13 (03) : 285 - 291
  • [43] Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis
    Snyder, KM
    Stock, RG
    Hong, SM
    Lo, YC
    Stone, NN
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (02): : 335 - 341
  • [44] The Effect of Inter-Seed Attenuation and Tissue Composition in Prostate 125I Brachytherapy Dose Calculations
    Tamura, K.
    Araki, F.
    Ohno, T.
    MEDICAL PHYSICS, 2016, 43 (06) : 3471 - 3472
  • [45] Is scintigraphy necessary to detect migration of 125I seeds after brachytherapy for early prostate cancer?
    Yu Odagaki
    Makoto Ohori
    Mana Yoshimura
    Jun Nakshima
    Yoshio Ohno
    Ryuji Mikami
    Hidetsugu Nakayama
    Koichi Tokuuye
    Masaaki Tachibana
    International Journal of Clinical Oncology, 2016, 21 : 397 - 401
  • [46] The risk of second malignancies after 125I prostate brachytherapy as monotherapy in a single Australian institution
    Ots, Ana Fernandez
    Browne, Lois
    Chin, Yaw Sinn
    Malouf, David
    Wong, Keith
    Bucci, Joseph
    BRACHYTHERAPY, 2016, 15 (06) : 752 - 759
  • [47] Is scintigraphy necessary to detect migration of 125I seeds after brachytherapy for early prostate cancer?
    Odagaki, Yu
    Ohori, Makoto
    Yoshimura, Mana
    Nakshima, Jun
    Ohno, Yoshio
    Mikami, Ryuji
    Nakayama, Hidetsugu
    Tokuuye, Koichi
    Tachibana, Masaaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (02) : 397 - 401
  • [48] In vivo detection of an 125I seed located in the intracardiac region after prostate permanent brachytherapy
    Blair, HF
    Porter, A
    Chen, QS
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03): : 888 - 891
  • [49] 125I brachytherapy for localized prostate cancer: a single institution experience
    Guarneri, Alessia
    Botticella, Angela
    Filippi, Andrea Riccardo
    Munoz, Fernando
    Beltramo, Giancarlo
    Casetta, Giovanni
    Giglioli, Francesca Romana
    Tizzani, Alessandro
    Ragona, Riccardo
    Ricardi, Umberto
    TUMORI JOURNAL, 2013, 99 (01): : 83 - 87
  • [50] Quadrant dosimetry as a predictor of biochemical relapse in 125I prostate brachytherapy
    Spadinger, Ingrid
    Morris, W. James
    Keyes, Mira
    Liu, Mitchell
    Shaffer, Richard
    Thompson, Anna
    Chng, Nicholas
    Woods, Ryan
    BRACHYTHERAPY, 2011, 10 (02) : 87 - 97